By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – German biotech firm Protagen today announced it will be using its UNIarray platform to support Biogen Idec's efforts in finding therapies for multiple sclerosis.

Under the terms of the agreement, the UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS. Protagen will also apply its expertise in autoantibody research to the alliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.